REG - ValiRx PLC - ValiRx forms ValiRx Animal Health Ltd subsidiary

ValiRxAnnouncement

02/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260302:nRSB8822Ua&default-theme=true

RNS Number : 8822U  ValiRx PLC  02 March 2026

2 March 2026

 

ValiRx PLC

("ValiRx" or the "Company")

 

ValiRx sets up wholly owned Subsidiary ValiRx Animal Health LTD

 

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on
early-stage cancer therapeutics and women's health is pleased to announce that
it has set up a wholly owned subsidiary ValiRx Animal Health Limited ("ValiRx
Animal Health").

ValiRx Animal Health has been incorporated to develop and commercialise
ValiRx's existing and future oncology assets in the veterinary market. The
study of naturally occurring tumours in dogs can inform research into
treatments for all types of cancer, including human cancer which often closely
resemble each other given that pets share our environment and exposures.
Comparative oncology integrates evaluation of therapeutics and biomarkers in
veterinary patients with human therapy development and increased interests in
advanced treatments for companion animals means there is an opportunity for
pets to receive better treatments whilst providing ethical models for human
clinical development.

ValiRx Animal Health will benefit from preclinical development work in the
Company's human programmes which will then benefit from early clinical read
outs to support partnering and human clinical trials.  The Board believe that
this strategy could lead to earlier commercial opportunities for these assets
with Veterinary Pharma partners. Several specialist Veterinary Venture Capital
funds have been identified and initial approaches made with the intention that
ValiRX Vet will be independently funded.

The Veterinary Oncology market was estimated at $1.58 billion in 2024 and is
projected to hit nearly $4.86 billion by 2034 with a CAGR of 12.14% throughout
the forecast timeline(1). The global veterinary oncology market is growing
significantly, driven by increasing prevalence of cancer among companion
animals, rising pet ownership and advancements in diagnostic imaging and
targeted therapies.

(1)2025 report by Towards Healthcare

Mark Eccleston, CEO of ValiRx commented "I have spoken previously about our
plan to develop our therapeutic portfolio for the benefit of animals as well
as humans having previously been involved in the successful development,
launch and $28 million sale of a cancer screening test for dogs. So, I am
excited that we have now moved forward with plans to set up a dedicated
Veterinary subsidiary. There is a strong scientific rationale, as well as
market opportunities, for this ethical approach and several examples of
companies that have followed this route. As with all our programmes, we have
carried out extensive due diligence into the markets and, working with our
advisory board, we have identified three key areas - Osteosarcoma, Lymphoma
and Hemangiosarcoma.

"Osteosarcoma in dogs is particularly interesting for complementary
development as it closely resembles human paediatric osteosarcoma. Whilst
prevalent in dogs, it is a rare but deadly condition in children. Pet patients
can therefore generate valuable clinical data to support human translation
whilst potential for Orphan Drug Designation in humans offers attractive
market exclusivity benefits in rare diseases. Also, given the high unmet need,
regulatory approval can be expedited meaning lower investment costs and faster
launches. Our CRO, Inaphaea Biolabs has Osteosarcoma PDC models allowing rapid
in-vitro screening using our New Approach Methodology. These all align with
ValiRx's strategy of smarter development."

 

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/peg6vy (https://valirx.com/link/PBvBVP)

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUPUPPWUPQGBG



            Copyright 2019 Regulatory News Service, all rights reserved